Currently, several clinical trials, e.g., “A Study to Evaluate Myeloma-Developing Regimens Using Genomics (MyDRUG, NCT02884102)” for patients with ≥30% mutation of CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2, or translocation t(11;14), and “Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial, NCT02465060)” address this question. This evidence concerns the gene NRAS and plasma cell myeloma.